Womenra: Restore Female Sexual Desire and Satisfaction
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.02 | $50.17 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $100.34 $60.21 (40%) | 🛒 Add to cart |
| 30 | $2.34 | $150.52 $70.24 (53%) | 🛒 Add to cart |
| 60 | $1.51 | $301.03 $90.31 (70%) | 🛒 Add to cart |
| 90 | $1.23 | $451.55 $110.38 (76%) | 🛒 Add to cart |
| 120 | $1.17 | $602.07 $140.48 (77%) | 🛒 Add to cart |
| 180 | $1.00 | $903.10 $180.62 (80%) | 🛒 Add to cart |
| 270 | $0.89 | $1354.66 $240.83 (82%) | 🛒 Add to cart |
| 360 | $0.84
Best per pill | $1806.21 $301.03 (83%) | 🛒 Add to cart |
Womenra is a prescription medication specifically formulated to address hypoactive sexual desire disorder (HSDD) in premenopausal women. It represents a significant advancement in the treatment of this complex condition, offering a targeted approach to rekindle libido and improve overall sexual experience. By acting on key neurotransmitters in the brain, it helps to rebalance the biological pathways responsible for sexual motivation and response, providing a clinically proven solution for women seeking to reclaim their sexual wellness.
Features
- Active Pharmaceutical Ingredient: Flibanserin 100mg
- Pharmacological Class: Multifunctional Serotonin Agent (5-HT1A receptor agonist and 5-HT2A receptor antagonist)
- Dosage Form: Oral tablet
- Recommended Administration: Once daily at bedtime
- Prescription Status: Available by prescription only following a comprehensive medical consultation
Benefits
- Clinically proven to increase the number of satisfying sexual events (SSEs) per month.
- Helps restore spontaneous sexual desire and reduce associated distress.
- Works by modulating brain chemistry to address the neurobiological imbalance associated with HSDD.
- Offers a non-hormonal treatment option for premenopausal women.
- Improves overall sexual well-being and intimacy-related feelings.
- Provides a targeted therapeutic approach with a defined mechanism of action.
Common use
Womenra is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent or recurrent deficiency (or absence) of sexual fantasies and desire for sexual activity, which causes marked distress or interpersonal difficulty. The diagnosis is not made better accounted for by a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. It is specifically for women who have not had problems with low sexual desire in the past but have developed them. It is intended for use in conjunction with a therapeutic approach that may include psychological counseling.
Dosage and direction
The recommended dosage is one 100 mg tablet taken orally once per day, at bedtime. Administration at bedtime is critical to mitigate the risk of certain side effects, such as hypotension and syncope, which are more likely to occur if the patient is upright. The tablet should be swallowed whole with a glass of water. It can be taken with or without food, but consistent administration relative to food intake is advised. Patients must not consume alcohol during treatment with Womenra due to a significant risk of severe hypotension and syncope. It is not intended for use in postmenopausal women or in men. Efficacy and safety of use beyond the studied period have not been systematically evaluated.
Precautions
Prior to initiating treatment, a thorough assessment of the patient’s overall health status is mandatory. Patients should be advised of the risk of hypotension and syncope, particularly in the initial weeks of therapy or following a dosage increase. Caution is advised when engaging in activities requiring full alertness, such as driving or operating machinery, the morning after taking Womenra, until the patient knows how the medication affects them. Hepatic impairment significantly increases flibanserin exposure; therefore, Womenra is contraindicated in patients with hepatic impairment. Patients should be monitored for somnolence (drowsiness) and advised on proper management. A careful evaluation of all current medications is necessary to avoid potentially dangerous interactions.
Contraindications
Womenra is contraindicated in the following patient populations and circumstances:
- Patients with known hypersensitivity to flibanserin or any of the tablet’s excipients.
- Patients with hepatic impairment.
- Concomitant use with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, erythromycin, grapefruit juice).
- Concomitant use with alcohol.
- Postmenopausal women and men, as safety and efficacy have not been established.
- Patients with a history of hypotension or who are being treated with antihypertensive medications or other drugs that can lower blood pressure.
Possible side effect
Like all medicines, Womenra can cause side effects, although not everybody gets them. The most commonly reported adverse reactions are:
- Dizziness
- Somnolence (sleepiness, drowsiness)
- Nausea
- Fatigue
- Insomnia
- Dry mouth
- Hypotension (low blood pressure)
- Syncope (fainting) These side effects are often dose-related and may be more pronounced upon initiation of therapy. Patients should be instructed to report any persistent or severe side effects to their healthcare provider immediately. Syncope requires immediate medical attention.
Drug interaction
Womenra is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system and, to a lesser extent, by CYP2C19. This creates a high potential for significant drug-drug interactions.
- Strong/Moderate CYP3A4 Inhibitors: Concomitant use is contraindicated. These drugs (e.g., ketoconazole, itraconazole, nefazodone, clarithromycin, fluconazole, grapefruit juice) drastically increase flibanserin plasma concentrations, elevating the risk of severe hypotension and syncope.
- CYP2C19 Inhibitors: Concomitant use with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine) may increase flibanserin exposure. Use with caution and monitor for adverse reactions.
- CNS Depressants: Concomitant use with other central nervous system (CNS) depressants (e.g., benzodiazepines, narcotics, antipsychotics, antidepressants, sedating antihistamines) may potentiate sedative effects and increase the risk of somnolence and fatigue.
- Other Hypotensive Agents: Concomitant use with medications that lower blood pressure may increase the risk of hypotension, dizziness, and syncope.
Missed dose
If a dose is missed at bedtime, the patient should skip that dose and take the next tablet at the usual time the following bedtime. Patients must never take a double dose to make up for a forgotten tablet. Taking more than the prescribed 100 mg dose within a 24-hour period significantly increases the risk of severe adverse effects, including syncope and hypotension.
Overdose
In case of suspected overdose, which may involve taking more than one 100 mg tablet in a 24-hour period, immediate medical attention must be sought. Symptoms of overdose are likely to be an exaggeration of the known adverse effects, including severe sedation (somnolence), profound dizziness, and pronounced hypotension potentially leading to cardiovascular collapse. There is no specific antidote for flibanserin overdose. Treatment should consist of general supportive measures, including continuous cardiovascular monitoring. Due to high protein binding, flibanserin is not expected to be dialyzable.
Storage
Store Womenra tablets at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original blister pack or bottle to protect it from light and moisture. Always keep all medicines out of the sight and reach of children and pets. Do not use the medicine after the expiration date printed on the packaging. Properly dispose of any unused or expired medication as directed by a pharmacist or through a medicine take-back program.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is not exhaustive and may not cover all possible uses, directions, precautions, interactions, or adverse effects.
Reviews
“After struggling with a complete lack of libido for years, which was causing significant distress in my relationship, my doctor and I decided to try Womenra. The first few weeks I experienced some drowsiness, but taking it right before bed managed that. After about two months, I noticed a genuine return of spontaneous desire. It wasn’t a ‘magic pill,’ but it gave me the biological push I needed to reconnect with that part of myself. It’s been a crucial part of regaining my sexual wellness.” - S.P., Age 38
“My journey with HSDD was frustrating. Counseling helped with the emotional aspects, but I felt there was a biological block. Since starting Womenra, the distressing absence of desire has lifted. I have more frequent and more satisfying sexual events with my partner. The key for me was being patient; the full effects weren’t immediate. The requirement to avoid alcohol is a lifestyle adjustment, but one I find worthwhile for the benefit.” - J.L., Age 42
“I was initially very skeptical, but my gynecologist explained the science behind it. The strict no-alcohol rule and the potential for dizziness were concerning, but I experienced minimal side effects (a bit of fatigue for the first week). For me, the most significant change has been the reduction in the anxiety and distress I felt about my lack of interest. Feeling ’normal’ again in this aspect of my life has been profoundly positive.” - M.K., Age 35